Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ACADIA Pharmaceuticals Inc

ACAD
Current price
22.29 USD -0.4 USD (-1.76%)
Last closed 22.85 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 710 468 096 USD
Yield for 12 month +49.60 %
Week
Month
Year
ACAD
21.11.2021 - 28.11.2021

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California. Address: 12830 El Camino Real, San Diego, CA, United States, 92130

Analytics

WallStreet Target Price

32.75 USD

P/E ratio

Dividend Yield

5.43 %

Current Year

+517 235 000 USD

Last Year

+484 145 000 USD

Current Quarter

+211 699 000 USD

Last Quarter

+165 235 000 USD

Current Year

+507 069 000 USD

Last Year

+465 004 000 USD

Current Quarter

+197 077 000 USD

Last Quarter

+157 776 000 USD

Key Figures ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -149 982 000 USD
Operating Margin TTM -27.29 %
PE Ratio
Return On Assets TTM -15.63 %
PEG Ratio -0.42
Return On Equity TTM -37.78 %
Wall Street Target Price 32.75 USD
Revenue TTM 631 886 016 USD
Book Value 2.21 USD
Revenue Per Share TTM 3.87 USD
Dividend Share
Quarterly Revenue Growth YOY 62 %
Dividend Yield 5.43 %
Gross Profit TTM 145 494 000 USD
Earnings Share -0.91 USD
Diluted Eps TTM -0.91 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -23.55 %

Dividend Analytics ACAD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 5.43 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACAD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 31.348
Enterprise Value Revenue 5.4124
Price Sales TTM 5.8721
Enterprise Value EBITDA -22.8031
Price Book MRQ 10.2405

Financials ACAD

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ACAD

For 52 weeks

14.45 USD 33.99 USD
50 Day MA 22.63 USD
Shares Short Prior Month 7 541 573
200 Day MA 23.44 USD
Short Ratio 5.19
Shares Short 7 786 335
Short Percent 6.34 %